U.S. Software Stock News

NasdaqGS:CTSH
NasdaqGS:CTSHIT

Is Cognizant (CTSH) Pricing Reflect Its Role In Global Digital Transformation Services

If you are wondering whether Cognizant Technology Solutions at around US$85.61 is offering good value today, you are not alone, and the numbers give us plenty to work with. The stock has recently shown a 1.0% return over the past week, 0.0% over the last 30 days, 5.3% year to date, 7.2% over 1 year, 37.8% over 3 years, and 17.3% over 5 years, which gives useful context before comparing price to underlying value. Recent news around Cognizant has focused on its position as a global IT services...
NasdaqGS:POWL
NasdaqGS:POWLElectrical

Powell Industries Coverage Highlights Acquisition Valuation Concerns And Recent Momentum

Powell Industries (NasdaqGS:POWL) has received initial coverage from Cantor Fitzgerald, focusing on the recent acquisition of Remsdaq. The acquisition is intended to expand the company’s automation and software capabilities within its existing operations. Powell Industries has also updated its executive compensation structure, indicating an internal response to its ongoing corporate plans. For investors watching Powell Industries at a current share price of $423.44, these moves follow a...
NYSE:DGX
NYSE:DGXHealthcare

Is It Time To Reassess Quest Diagnostics (DGX) After Its Mixed Recent Share Price Moves

If you are wondering whether Quest Diagnostics at around US$182 per share is offering fair value right now, you are not alone. The answer depends on which valuation lens you use. The stock has seen mixed recent returns, with a 3.7% decline over the last 7 days, a 3.7% gain over the last 30 days, a 5.0% return year to date, and a 16.2% return over the past year, alongside 33.0% and 51.0% returns over 3 and 5 years respectively. Recent headlines around Quest Diagnostics have focused on its...
NasdaqCM:LMB
NasdaqCM:LMBConstruction

Did Limbach’s New Customer and Sales EVPs Just Reframe LMB’s Owner-Direct Investment Narrative?

Limbach Holdings, Inc. recently appointed long-time leaders Nick Angerosa as Executive Vice President, National Customer Solutions, and Jay Sharp as Executive Vice President, Sales, effective January 13, 2026, formalizing their expanded roles after years of regional leadership within the company. The elevation of two deeply tenured insiders to focus on customer solutions and sales execution highlights Limbach’s emphasis on strengthening owner-direct relationships and aligning commercial...
NasdaqGS:INDV
NasdaqGS:INDVPharmaceuticals

Will Indivior’s (INDV) US Headquarters Shift and Larger ESOP Shelf Reshape Its Corporate Narrative?

Indivior Pharmaceuticals, Inc. recently completed its move of corporate headquarters to the US, creating a new Delaware-based parent while closing a prior US$80.46 million ESOP-related shelf registration and filing a new US$569.10 million ESOP-focused shelf for common stock. This restructuring not only concentrates governance and financing in the company’s largest market but also simplifies reporting, lending arrangements and future equity-based employee programs. We will examine how...
OTCPK:VXRT
OTCPK:VXRTBiotechs

Does Vaxart’s (VXRT) Early Norovirus Infant Data Hint At A Broader Oral Vaccine Platform Advantage?

Vaxart, Inc. recently reported in npj Vaccines that its double-blind, placebo-controlled Phase 1 trial of a single-dose oral bivalent norovirus vaccine in breastfeeding women showed vaccine-induced functional norovirus-specific antibodies in maternal breastmilk and serum, as well as norovirus-specific IgA in the stool of their breastfed infants, with the vaccine remaining safe and well tolerated. The finding of a positive correlation between breast milk IgA levels and infant stool IgA offers...